Navellier & Associates Inc Ligand Pharmaceuticals Inc Transaction History

Navellier & Associates Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$68.28 - $123.65 $252,636 - $457,505	-3,700 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$96.94 - $113.59 $43,138 - $50,547	-445 Reduced 10.74%	3,700 $386,000
Q3 2019 Oct 16, 2019	BUY	$86.25 - $120.16 $3,450 - $4,806	40 Added 0.97%	4,145 $413,000
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $2,118 - $2,849	-20 Reduced 0.48%	4,105 $516,000
Q4 2018 Jan 15, 2019	SELL	$128.36 - $272.13 $1.04 Million - $2.2 Million	-8,066 Reduced 66.16%	4,125 $560,000
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $494,583 - $642,855	2,342 Added 23.78%	12,191 $3.35 Million
Q2 2018 Aug 06, 2018	BUY	$150.77 - $207.98 $121,822 - $168,047	808 Added 8.94%	9,849 $2.04 Million
Q1 2018 May 21, 2018	BUY	$138.63 - $182.62 $679,425 - $895,020	4,901 Added 118.38%	9,041 $1.49 Million
Q4 2017 Feb 12, 2018	BUY	$128.36 - $147.04 $531,410 - $608,745	4,140 New	4,140 $567,000
Q3 2017 Nov 14, 2017	SELL	$120.91 - $137.94 $500,567 - $571,071	-4,140 Closed	0 $0
Q2 2017 Aug 24, 2017	BUY	N/A	4,140	4,140 $503,000

275

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.98B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.